Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

C. Byrd, John; K. Harrington, Bonnie; O’Brien, Susan; A. Jones, Jeffrey; Schuh, Anna; Devereux, Steve; Chaves, Jorge; G. Wierda, William; T. Awan, Farrukh; R. Brown, Jennifer; Hillmen, Peter; M. Stephens, Deborah; Ghia, Paolo; C. Barrientos, Jacqueline; M. Pagel, John; A. Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; J. Lannutti, Brian; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; G. Diacovo, Thomas; J. Johnson, Amy; R. Furman, Richard

doi:10.1056/nejmoa1509981

Public

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Published in New England Journal of Medicine • Dec 8, 2015

Authors:

John C. Byrd

Bonnie K. Harrington

Susan O’Brien

Abstract

BACKGROUND: Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeu...

Subject

Bruton's tyrosine kinase

Ibrutinib

Chronic lymphocytic leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!